BioNTech testing vaccine effect against new variant

Friday, 26. November 2021 14:15

BioNTech SE said on Friday that it is testing the effectiveness of its Comirnaty vaccine, co-developed with Pfizer Inc, against the new southern African variant of COVID-19.

BioNTech stated that it expects "further data from the laboratory tests in two weeks at the latest." The firms aim to be able to adapt their mRNA vaccine within six weeks of any variant discovery and subsequently deliver batches within 100 days.

Share values of vaccine makers surged early on Friday as markets conversely plunged in response to fears of the new variant's potential effects on the global economy.

Related Links: Pfizer Inc.BioNTech SE
Author:
Baha Breaking the News (BBN) / IB